Gyre Therapeutics Inc. (GYRE) — Capital Reinvestment Ratio
Gyre Therapeutics Inc. (GYRE) has a Capital Reinvestment Ratio of 0.15x as of September 2025, meaning it reinvests 0% of its operating cash flow ($4.68 Million) in capital expenditures ($683.00K). See Gyre Therapeutics Inc. net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Gyre Therapeutics Inc. Capital Reinvestment Ratio (2007–2023)
This chart tracks Gyre Therapeutics Inc.'s Capital Reinvestment Ratio across 4 annual periods. Check GYRE cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Gyre Therapeutics Inc. (2007–2023)
Year-by-year Capital Reinvestment Ratio for Gyre Therapeutics Inc. from 2007 to 2023. For live market cap and broader valuation context, see Gyre Therapeutics Inc. (GYRE) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.33x | $25.89 Million | $8.59 Million | ▼ -29.2% |
| 2022 | 0.47x | $10.68 Million | $5.00 Million | ▲ +1855.3% |
| 2010 | 0.02x | $138.30 Million | $3.31 Million | ▼ -88.0% |
| 2007 | 0.20x | $24.84 Million | $4.94 Million | — |